Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmuneNet: LF-EMR for Autoimmune Diseases
NCT07221565Phase 2Enrolling by invitation
- Start
- Oct 2025
- Primary completion
- Oct 2034
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS) (2 arms). Primary endpoint: Change in Autoimmune Flare Frequency at 6 months. Started Oct 2025; status: enrolling by invitation.
02
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07221565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221565.